Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Plasma Proneurotensin Levels Predict Breast Cancer

By LabMedica International staff writers
Posted on 14 Jan 2013
A simple blood test for the determination of proneurotensin (pro-NT) shows promise as a starting point for the prevention of breast cancer. More...
The test will be available in Europe beginning in the second quarter of 2013.

Sphingotec GmbH (Hennigsdorf, Germany) will launch the blood test, Sphingotest pro-NT, for the early prediction of breast cancer in women. The new test detects the release of the satiety hormone neurotensin and is applicable to all female individuals, regardless of genetic predispositions. Data demonstrating that determination of proneurotensin levels offers a substantial advantage in prediction of breast cancer was recently published in the October 10, 2012, Journal of the American Medical Association (JAMA).

Neurotensin is a satiety hormone, released in gastrointestinal tract. The major stimulus for neurotensin production is fat. Breast cancer-cell growth is stimulated by neurotensin. Because neurotensin is a very unstable peptide, Sphingotec uses the stable precursor hormone proneurotensin as a surrogate biomarker for neurotensin. High levels of proneurotensin correspond with a three-fold risk of developing breast cancer or a recurrence of breast cancer.

"Sphingotec will offer a simple blood test that can be used by gynecologists, family doctors and clinical laboratories for women to quantify their individual risk to develop breast cancer," said Dr. Andreas Bergmann, CEO of Sphingotec GmbH. "We are confident this test will impact current prevention and early recognition programs for breast cancer and ultimately breast cancer incidence as well."

Sphingotec GmbH is a biotechnology company that aims to reduce incidence of severe diseases like cancer and diabetes by identification of susceptibility factors. The company explores biomarkers that are susceptibility factors for the development of severe diseases and provides starting points for prevention strategies.

Related Links:

Sphingotec GmbH



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.